Cited by 70Amino Acid Enzymes and MetabolismCancer, Hypoxia, and MetabolismPI3K/AKT/mTOR signaling in cancer

Glutamine synthetase limits β-catenin–mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1

Open access
Dai, Weiwei, Shen, Jianliang, Yan, Junrong, Bott, Alex J., Maimouni, Sara, Daguplo, Heineken Q., Wang, Yujue, Khayati, Khoosheh +9 more·2022·Journal of Clinical Investigation

Abstract

Glutamine synthetase (GS) catalyzes de novo synthesis of glutamine that facilitates cancer cell growth. In the liver, GS functions next to the urea cycle to remove ammonia waste. As a dysregulated urea cycle is implicated in cancer development, the impact of GS's ammonia clearance function has not been explored in cancer. Here, we show that oncogenic activation of β-catenin (encoded by CTNNB1) led to a decreased urea cycle and elevated ammonia waste burden. While β-catenin induced the expression of GS, which is thought to be cancer promoting, surprisingly, genetic ablation of hepatic GS accelerated the onset of liver tumors in several mouse models that involved β-catenin activation. Mechanistically, GS ablation exacerbated hyperammonemia and facilitated the production of glutamate-derived nonessential amino acids, which subsequently stimulated mechanistic target of rapamycin complex 1 (mTORC1). Pharmacological and genetic inhibition of mTORC1 and glutamic transaminases suppressed tumorigenesis facilitated by GS ablation. While patients with hepatocellular carcinoma, especially those with CTNNB1 mutations, have an overall defective urea cycle and increased expression of GS, there exists a subset of patients with low GS expression that is associated with mTORC1 hyperactivation. Therefore, GS-mediated ammonia clearance serves as a tumor-suppressing mechanism in livers that harbor β-catenin activation mutations and a compromised urea cycle.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci161408

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 69 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Dai, W., Shen, J., Yan, J., Bott, A. J., Maimouni, S., Daguplo, H. Q., Wang, Y., Khayati, K., Guo, J. Y., Zhang, L., Wang, Y., Valvezan, A., Ding, W.-X., Chen, X., Su, X., Gao, S., & Zong, W.-X.
Affiliations
  • Rutgers, The State University of New Jersey (US)
  • University of Kansas Medical Center (US)
  • University of California, San Francisco (US)
  • Shanghai Medical College of Fudan University (CN)
Corresponding author
Zong, Wei-Xing
Venue
Journal of Clinical Investigation
Published
2022-12-15
Volume
132
Issue
24
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4306708210
Cited by
70
References
69
Citations by year
2026: 11 · 2025: 33 · 2024: 15 · 2023: 10 · 2022: 1
FWCI
6.25
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
National Cancer Institute (R01CA129536,R01CA224550,R01CA250227)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
glutamine synthetase, β-catenin, CTNNB1 mutation, liver cancer, hepatocellular carcinoma, urea cycle, ammonia clearance, hyperammonemia, nitrogen homeostasis, mTORC1, glutamate transaminases, tumor suppression, non-essential amino acids
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Ammonia, Animals, Glutamine, Glutamate-Ammonia Ligase, Homeostasis, Liver, Liver Neoplasms, Nitrogen, Urea, beta Catenin, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review